الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 132 |  |  |
| | | from | 132 | | |
Abstract
Compared with anuric dialysis patients, those with RRF have, in
essence, a bonus with respect to solute clearance that, in addition to its
contribution to Kt/V urea, is continuous and particularly effective at removing
toxins not cleared well by dialysis. Additional benefits are associated with the
accompanying increase in urine volume. Accordingly, guarding and
preserving RRF in dialysis patients should be a high priority. Unfortunately,
investigation in this area has been deficient. Benefits from ACEI and ARB
therapy in small studies have been described and will need to be investigated
further. Better understanding of potential risk factors for residual GFR loss
including DM, BMI, dialysis modality, volume depletion, and of CKD
therapies (traditional and novel) such as RAAS inhibitors, statins, and vitamin
D are needed. All of these factors seem to share a common final pathway to
residual GFR loss involving inflammation, proliferation, and fibrosis.
Proposed treatment regimens appear to have overlapping and synergistic
activity and should be considered for future investigation
Inflammation as an essential part of chronic kidney disease (CKD) has
been recognized in the late 1990s, when it was linked to cardiovascular
disease, protein-energy wasting, and mortality Over the past 15 years, there
has been an exponential growth of interest in inflammation in CKD and endstage
renal disease (ESRD), which led to the evolution in our perception of
inflammation as not any longer a novel but rather a well-established, if not
traditional risk factor of morbidity and mortality in CKD.
This study was carried out on a fifty patients on regular haemodialysis
sessions in haemodialysis unit of Nasr city hospital of insurance. All will be
given informed consent.
Study Groups